Informatie:
Fout:
ID
34177
Beschrijving
Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers; ODM derived from: https://clinicaltrials.gov/show/NCT02098954
Link
https://clinicaltrials.gov/show/NCT02098954
Trefwoorden
Versies (1)
- 15-01-19 15-01-19 -
Houder van rechten
GSK group of companies
Geüploaded op
15 januari 2019
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Carcinoma, Non-Small Cell Lung NCT02098954
Eligibility Carcinoma, Non-Small Cell Lung NCT02098954
- StudyEvent: Eligibility
Similar models
Eligibility Carcinoma, Non-Small Cell Lung NCT02098954
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
ID.1
Item
advanced non-small cell lung cancer, stage iiib/iv
boolean
ID.2
Item
non-squamous
boolean
ID.3
Item
egfr sensitive mutations, such as exon 19 del, or exon 21 l858r
boolean
ID.4
Item
received first line tkis treatment and developed tki resistance
boolean
ID.5
Item
ecog 0-2
boolean
ID.6
Item
squamous non-small cell lung cancer
boolean
ID.7
Item
patients have unstable brain metastasis, predict survival less than 8 weeks
boolean
ID.8
Item
spinal-cord compression without evidence of stabilisation or treatment
boolean
ID.9
Item
women who were pregnant or lactating; women with a positive or no available pregnancy test result at baseline
boolean
ID.10
Item
patients have any unstable illness that could not receive further treatment
boolean